Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.64 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.63 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675271 | 0.90 | MAPT (0.63) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL5597699 | 0.89 | KMT2A (0.90) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL30101230 | 0.89 | KMT2A (0.90) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL4548162 | 0.87 | KMT2A (0.87) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL1463492 | 0.86 | MAPT (0.58) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL1463167 | 0.85 | KDR (0.73) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL8368360 | 0.84 | TRPV1 (0.67) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL17609423 | 0.84 | MAPT (1.00) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL17664317 | 0.84 | KMT2A (0.81) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL30069239 | 0.84 | MAPT (1.00) | KMT2AMAPTMEN1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | claimed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | claimed |
| CN-1845726-A | Erg channel openers for the treatment of cardiac arrhythmias | POSEIDON PHARMACEUTICALS AS (DK) | 2006-10-11 | — | — | CN | claimed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | OLESEN SOEREN PETER | 2011-03-24 | — | — | US | disclosed |
| US-7851492-B2 | ERG channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| CN-1845726-A | Erg channel openers for the treatment of cardiac arrhythmias | POSEIDON PHARMACEUTICALS AS (DK) | 2006-10-11 | — | — | CN | disclosed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | KCNJ2, KCNN3, KCNE1 | KMT2A 2189/4885MAPT 4034/4885MEN1 2084/4885 |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | KCNJ2, KCNN3, KCNE1 | KMT2A 2189/4885MAPT 4034/4885MEN1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.